Abstract
HIV infects and propagates into CD4+T lymphocytes and macrophages, although many other cell types play an important role in virus spreading and pathogenesis. In addition to regulatory viral proteins, the cytokine network has early been implicated as a major controller of the plastic capacity of HIV to spread productively or rather remain silently integrated in the chromosomes of infected cells. The recent discovery of CCR5 and CXCR4 as essential entry co-receptors together with CD4 has highlighted a novel and potentially important step in the pharmacological hunt for more effective antiviral agents. In addition to regulate HIV expression and replication, several cytokines have demonstrated the capacity of up- or down-modulating chemokine receptors including CCR5 and CXCR4 with the consequence of influencing the susceptibility of T cells and macrophages to HIV infection. Pharmacological agents such as pertussis toxin B-oligomer have demonstrated HIV suppressive effects via non competitive binding of CCR5, whereas interferons or interleukin-16 (IL-16) can prevent post-entry steps in HIV expression. At the clinical level, several cytokines or their receptors are useful markers for monitoring disease progression and its consequence on the immune system. Cytokine-based therapy represents a realistic complementary approach to traditional antiretroviral therapy potentially capable of restoring important adaptive or innate immune functions ultimately curtailing HIV spreading and its consequences on the immune system, as exemplified by the experimental clinical use of IL-2.
Keywords: Cytokine, Chemokine, HIV Infection, Replication, CD4+ T lymphocytes, CCR5, CXCR4, highly aggressive anti-retroviral therapy (HAART), plasma-associated HIV RNA, or viremia) inexorably, cytotoxic T
Current Pharmaceutical Design
Title: Cytokine and Chemokine Based Control of HIV Infection and Replication
Volume: 7 Issue: 11
Author(s): Massimo Alfano and Guido Poli
Affiliation:
Keywords: Cytokine, Chemokine, HIV Infection, Replication, CD4+ T lymphocytes, CCR5, CXCR4, highly aggressive anti-retroviral therapy (HAART), plasma-associated HIV RNA, or viremia) inexorably, cytotoxic T
Abstract: HIV infects and propagates into CD4+T lymphocytes and macrophages, although many other cell types play an important role in virus spreading and pathogenesis. In addition to regulatory viral proteins, the cytokine network has early been implicated as a major controller of the plastic capacity of HIV to spread productively or rather remain silently integrated in the chromosomes of infected cells. The recent discovery of CCR5 and CXCR4 as essential entry co-receptors together with CD4 has highlighted a novel and potentially important step in the pharmacological hunt for more effective antiviral agents. In addition to regulate HIV expression and replication, several cytokines have demonstrated the capacity of up- or down-modulating chemokine receptors including CCR5 and CXCR4 with the consequence of influencing the susceptibility of T cells and macrophages to HIV infection. Pharmacological agents such as pertussis toxin B-oligomer have demonstrated HIV suppressive effects via non competitive binding of CCR5, whereas interferons or interleukin-16 (IL-16) can prevent post-entry steps in HIV expression. At the clinical level, several cytokines or their receptors are useful markers for monitoring disease progression and its consequence on the immune system. Cytokine-based therapy represents a realistic complementary approach to traditional antiretroviral therapy potentially capable of restoring important adaptive or innate immune functions ultimately curtailing HIV spreading and its consequences on the immune system, as exemplified by the experimental clinical use of IL-2.
Export Options
About this article
Cite this article as:
Alfano Massimo and Poli Guido, Cytokine and Chemokine Based Control of HIV Infection and Replication, Current Pharmaceutical Design 2001; 7 (11) . https://dx.doi.org/10.2174/1381612013397591
DOI https://dx.doi.org/10.2174/1381612013397591 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: How Brain Faces Stressors, Regulates Stress Response and Undergoes Stress Consequences (Guest Editor: Juan C. Leza)]
CNS & Neurological Disorders - Drug Targets Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII
Cardiovascular & Hematological Disorders-Drug Targets Domestic Arthropods and Their Allergens
Protein & Peptide Letters Treatment Failure in Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Bioactive Metabolites from Pathogenic and Endophytic Fungi of Forest Trees
Current Medicinal Chemistry Pharmacokinetics Prediction and Drugability Assessment of Diphenylheptanoids from Turmeric (Curcuma longa L)
Medicinal Chemistry Impact of Hyperhomocyst(e)inemia on Endothelial Function
Vascular Disease Prevention (Discontinued) Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases
Current Pharmacogenomics Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism The Impact of Docosahexaenoic Acid on Alzheimer’s Disease: Is There a Role of the Blood-Brain Barrier?
Current Clinical Pharmacology Humanized Mouse Models of HIV-1 Latency
Current HIV Research Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The Role of Alpha1-Antitrypsin Deficiency in Respiratory Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pertinence of Apoptosis Markers for the Improvement of In Vitro Fertilization (IVF)
Current Medicinal Chemistry Mast Cells in Tissue Healing: From Skin to the Gastrointestinal Tract
Current Pharmaceutical Design The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry